Lilly’s new leaf
How Lilly’s new R&D head aims to beef up the pharma’s first-in-class cache
As Daniel Skovronsky takes the helm of Eli Lilly and Co.’s R&D business, his goal is to shake the pharma’s reputation as a fast-follower and instead advance first-in-class therapeutics with large effect sizes. To get there, he is pushing for more early stage collaborations, building biotech-like structures within R&D, and exploring new modalities synergistic with Lilly’s expertise.
Skovronsky will take over as SVP for science and technology and president of Lilly Research Laboratories on June 1, succeeding Jan Lundberg, who is retiring. Skovronsky was previously SVP for clinical and product development and joined Lilly in 2010 when the pharma acquired Avid Radiopharmaceuticals Inc.
BioCentury sat down with Skovronsky as he prepares to begin the new role, joined by Levi Garraway, one of three academic clinicians Lilly hired into senior positions in the last two years. Garraway was an associate professor in the department of medical oncology at Dana-Farber Cancer Institute, and joined Lilly in September 2016 as SVP of global oncology.
Lilly’s pipeline has been dominated by next-in-class therapies. Of nine drugs launched since 2014, only one was first in class.
Skovronsky wants to change that by doing more preclinical and Phase I collaborations with biotechs and academics. The goal is to bring in new assets and modalities that complement Lilly’s existing strengths in areas such as diabetes.
Skovronsky is also transforming Lilly’s internal R&D organization. For example, he’s already moved the BD unit under the umbrella of R&D and created biotech-like organizations -- dubbed “trailblazers” -- inside target areas. The trailblazers have their own budgets